Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238396 | 0.85 | HRH3 (0.53) | PARP15PARP10PARP2MAPK1HRH3 | |
| SCHEMBL4236481 | 0.81 | HRH3 (0.54) | HRH3 | |
| SCHEMBL3581757 | 0.80 | KMT2A (0.55) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL3578863 | 0.80 | KMT2A (0.55) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL4236787 | 0.79 | HRH3 (0.54) | KDM2BALDH1A1HRH3 | |
| SCHEMBL2885506 | 0.78 | PARP10 (0.73) | PARP15PARP10PARP2MAPK1 | |
| SCHEMBL12420703 | 0.78 | PARP10 (0.73) | PARP15PARP10PARP2 | |
| SCHEMBL26729863 | 0.78 | CHRM3 (0.48) | MAPK1NPSR1ALDH1A1SRD5A2 | |
| SCHEMBL12420700 | 0.77 | PARP10 (0.74) | PARP15PARP10PARP2ALDH1A1 | |
| SCHEMBL1532862 | 0.77 | PARP10 (0.74) | PARP15PARP10PARP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| CN-101198604-A | NPY antagonists, their preparation and use | CEREP (FR) | 2008-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | KDM2B 2057/4885PARP15 2421/4885PARP10 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.